Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11000743 | 0.84 | HPGD (0.83) | HPGDMEN1KMT2APOLBAR | |
| SCHEMBL4493666 | 0.83 | HPGD (1.00) | HPGDMEN1KMT2APOLBAR | |
| SCHEMBL12678506 | 0.80 | HPGD (0.81) | HPGDMEN1KMT2APOLBAR | |
| SCHEMBL3872525 | 0.79 | HPGD (0.68) | HPGDMEN1KMT2APOLBAR | |
| SCHEMBL5742854 | 0.79 | HPGD (0.70) | HPGDMEN1KMT2AARHTT | |
| SCHEMBL3467606 | 0.76 | HPGD (1.00) | HPGDMEN1KMT2APOLBAR | |
| SCHEMBL14358427 | 0.75 | HPGD (0.68) | HPGDMEN1KMT2APOLBAR | |
| SCHEMBL9464414 | 0.75 | HPGD (0.68) | HPGDMEN1KMT2APOLBAR | |
| SCHEMBL14358426 | 0.75 | HPGD (0.68) | HPGDMEN1KMT2APOLBAR | |
| SCHEMBL5886620 | 0.75 | HPGD (0.68) | HPGDMEN1KMT2APOLBAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | HPGD 424/4885MEN1 3031/4885KMT2A 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.